Peter Smethurst

19 - 20 September 2019
Hilton Deansgate, Manchester

Speaker

  Peter  Smethurst

Peter Smethurst

Director of Patient Access to Care, Gilead Sciences

Peter is the Patient Access to Care Director for Gilead Sciences and responsible for leading Gilead’s Hepatitis C (HCV) elimination initiatives in England. Gilead Sciences was awarded Gold status in the NHSE HCV Elimination tender in April 2019 and are working closely with NHS England and other stakeholders to improve diagnosis and treatment of HCV across drug treatment services, prisons, needle exchange and improve disease awareness in South Asian populations.

Peter manages a field team that works with stakeholders to provide simple and effective care pathways within drug and alcohol services. In 2019, this team in conjunction with drug service provider Change, Grow, Live, was proud to receive an HSJ Partnership Award for the Best Pharmaceutical Partnership with the NHS.

Date of Preparation August 2019

Zinc Job Bag number HCV/UK/19-08/NM/2026

By continuing to use the site you agree to our cookies policy. Accept